Gail Lewis Phillips
Job title: Senior Scientist, Discovery Oncology
I head a translational research lab in Discovery Oncology at Genentech that investigates cell membrane receptors as targets for development of cancer therapeutics, with emphasis on the HER2/erbB2 pathway. Our early research efforts focused on biology and preclinical development of anti-HER2 antibodies for HER2-amplified breast cancer. This work contributed to the development and approval of both Trastuzumab and Pertuzumab. Subsequently, we developed antibody-drug conjugates (ADCs) designed to selectively deliver potent cytotoxic agents to HER2-positive tumor cells, resulting in approval of Trastuzumab emtansine (T-DM1) for HER2-positive early and metastatic breast cancer. We are currently exploring use of T-DM1 in other cancers that overexpress HER2 as well as investigating new HER2-directed ADCs utilizing cytotoxic agents with different mechanisms of action. We have since expanded our studies on ADCs to include exploration of different targets, different antibody formats and novel drugs for potential new ADCs.
Live Presenter Q&A 10:00 am
day: Day One
Legacy of HER2-Directed Therapies: Past, Present & Future 8:30 am
• The many discoveries in the area of HER2-targeted therapies stand on the shoulders of the development of trastuzumab • ADCs and small molecule kinase inhibitors are currently promising yet challenging modalities for treating HER2-positive cancer • Immune- and cell-based therapies such as bispecifics, vaccines and CAR-Ts are on the horizonRead more
day: Day One